Praliciguat

CAS No. 1628730-49-3

Praliciguat ( IW-1973 )

Catalog No. M26793 CAS No. 1628730-49-3

Praliciguat stimulates sGC in HEK-293 cells (EC50: 197 nM). Praliciguat is an effective and orally active soluble guanylate cyclase stimulator.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 206 Get Quote
5MG 348 Get Quote
10MG 537 Get Quote
25MG 858 Get Quote
50MG 1161 Get Quote
100MG 1557 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Praliciguat
  • Note
    Research use only, not for human use.
  • Brief Description
    Praliciguat stimulates sGC in HEK-293 cells (EC50: 197 nM). Praliciguat is an effective and orally active soluble guanylate cyclase stimulator.
  • Description
    Praliciguat stimulates sGC in HEK-293 cells (EC50: 197 nM). Praliciguat is an effective and orally active soluble guanylate cyclase stimulator. It also enhances NO signaling and acts as a vasodilator.
  • Synonyms
    IW-1973
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Alkyl/ether; Cleavable; PEGs
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1628730-49-3
  • Formula Weight
    534.4
  • Molecular Formula
    C21H14F8N6O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    OC(CNc1nc(ncc1F)-c1cc(-c2ccon2)n(Cc2ccccc2F)n1)(C(F)(F)F)C(F)(F)F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Carston R. Wagner, et al. Protein nanorings. US8236925B1.
molnova catalog
related products
  • Soyasaponin Aa

    Soyasaponin Aa and soyasaponin Ab dose-dependently markedly inhibit adipocyte differentiation and expression of various adipogenic marker genes, through the downregulation of the adipogenesis-related transcription factors PPARγ and C/EBPα± in 3T3-L1 adipocytes.

  • Bryodulcosigenin

    Bryodulcosigenin has anti-inflammatory effect, it shows potent inhibitory effects on EBV-EA induction.

  • Fenaclon

    Fenaclon is an anticonvulsant. It is indicated for the treatment of epilepsy.